262 related articles for article (PubMed ID: 32458521)
1. Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
Turashvili G; Wen HY
Breast J; 2020 Jun; 26(6):1199-1207. PubMed ID: 32458521
[TBL] [Abstract][Full Text] [Related]
2. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
[TBL] [Abstract][Full Text] [Related]
3. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Fujii T; Masuda H; Cheng YC; Yang F; Sahin AA; Naoi Y; Matsunaga Y; Raghavendra A; Sinha AK; Fernandez JRE; James A; Yamagishi K; Matsushima T; Schuetz R; Tripathy D; Tada S; Jackson RS; Noguchi S; Nakamura S; Acoba JD; Ueno NT
Breast Cancer Res Treat; 2021 Sep; 189(2):455-461. PubMed ID: 34131830
[TBL] [Abstract][Full Text] [Related]
4. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
5. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
7. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
8. Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Giorgi Rossi P; Lebeau A; Canelo-Aybar C; Saz-Parkinson Z; Quinn C; Langendam M; Mcgarrigle H; Warman S; Rigau D; Alonso-Coello P; Broeders M; Graewingholt A; Posso M; Duffy S; Schünemann HJ;
Br J Cancer; 2021 Apr; 124(9):1503-1512. PubMed ID: 33597715
[TBL] [Abstract][Full Text] [Related]
9. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
10. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Sparano JA; Gray RJ; Makower DF; Pritchard KI; Albain KS; Hayes DF; Geyer CE; Dees EC; Perez EA; Olson JA; Zujewski J; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Paik S; Wood WC; Ravdin P; Keane MM; Gomez Moreno HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Atkins JN; Berenberg JL; Sledge GW
N Engl J Med; 2015 Nov; 373(21):2005-14. PubMed ID: 26412349
[TBL] [Abstract][Full Text] [Related]
11. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
Henry NL; Braun TM; Ali HY; Munir K; Silver SM; Gorski DH; Breslin TM; Griggs JJ
Cancer; 2017 May; 123(6):948-956. PubMed ID: 27787892
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
[TBL] [Abstract][Full Text] [Related]
13. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
15. The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
O'Cearbhaill R; Gannon JM; Prichard RS; Walshe JM; McDermott E; Quinn CM
Pathobiology; 2019; 86(2-3):77-82. PubMed ID: 30347405
[TBL] [Abstract][Full Text] [Related]
16. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
17. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
18. Review of the clinical studies using the 21-gene assay.
Kelly CM; Warner E; Tsoi DT; Verma S; Pritchard KI
Oncologist; 2010; 15(5):447-56. PubMed ID: 20421266
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
[TBL] [Abstract][Full Text] [Related]
20. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Andre F; Ismaila N; Henry NL; Somerfield MR; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Van Poznak C; Wolff AC; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1956-1964. PubMed ID: 31150316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]